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Abstract 
A one-vial formulation of the chemotherapy agent Taxotere
® (docetaxel) is likely to be commercially available in some countries in 2010. 
Through control of two significant potential risk factors for crystallization—intervention into the infusion bag (by using a one-step 
technique) and temperature (by use of refrigerated storage)—it was postulated that the risk of precipitation would be reduced and the 
storage time of Taxotere
® increased using the one-vial formulation versus the two-vial formulation. Furthermore, improved convenience 
and flexibility were anticipated as a result of the easier and quicker preparation associated with the one-vial formulation versus the two-
vial formulation. The results of the physicochemical stability study presented here indicate that the one-vial formulation is indeed 
associated with reduced risk of precipitation of docetaxel. Moreover, refrigerated storage has been shown to extend the physical and 
chemical stability for up to seven days, versus 4 h for the currently approved two-vial formulation and 6 h for the one-vial formulation 
stored at room temperature. However, only physical and chemical stability have been assessed in this study. 
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Introduction 
Taxotere
®  (sanofi-aventis, Bridgewater, NJ) is a potent 
chemotherapeutic agent approved for use in breast cancer, 
non-small-cell lung cancer, metastatic castrate-resistant 
prostate cancer, gastric adenocarcinoma and squamous cell 
carcinoma of the head and neck [1–3].
 The active ingredient of 
Taxotere
® is docetaxel, which is a lipophilic molecule with a low-
aqueous solubility. To allow administration of the drug by 
infusion, docetaxel is solubilized by micelle formation with 
polysorbate 80. 
To achieve the required solubility, Taxotere
® has been 
packaged as a two-vial presentation since its introduction to the 
market in 1995. The two-vial presentation requires two dilutions 
prior to administration. The first vial (concentrate) contains 
docetaxel in polysorbate 80, at a concentration of 40 mg/ml. 
The second vial contains a 12% w/v ethanol/water diluent. 
When the entire extractable volume of the diluent vial is added 
to the concentrate vial and mixed, a 10 mg/ml intermediate 
(premix) solution of docetaxel is generated, which is then 
dispensed into an infusion solution containing 0.9% saline or 
5% dextrose for administration to the patient. An infusion 
solution prepared with 2-vial Taxotere
®, if stored at 2°C–25°C, is 
stable for 4  h according to the package information [1]. Data 
published by Thiesen and Kramer in 1999 suggested 
acceptable physicochemical stability for up to 28 days [4]; 
however, despite the increased potential for wastage and higher 
overall drug expenditures [5],
  the shorter 4-h expiry date is 
generally adhered to in practice because of a perceived lack of 
convincing experimental data in favour of the longer storage 
period and continued publication of conflicting data [6].   
The main reason for the short storage time is that there is a 
potential risk of crystallization of the Taxotere
® infusion solution 
during storage. The factors potentiating this risk include:  (a) 
insufficient mixing of the premix solution; (b) excessive 
agitation; (c) the presence of particles and surface irregularities; 
(d) physical interventions into the solution and (e) temperature.  
Insufficient mixing of the premix solution can lead to gel phase 
formation, which is transferred to the infusion bag and, in turn, 
can lead to precipitation of docetaxel through competition with 
micelle formation. Excessive agitation can lead to generation of 
additional nucleation sites through bubble formation, as well as 
imparting energy into the system, which promotes the 
achievement of equilibrium conditions. Nucleation would be 
expected to be promoted by particles in the solution, as well as
surface irregularities in the infusion bags. Physical interventions 
into the infusion solution, such as the introduction of a syringe 
needle into the solution, provide additional nucleation sites. 
Finally, temperature affects the kinetics of the release of 
docetaxel from the micelles in the supersaturated system. A 
lower temperature is expected to lead to stabilization of the 
micelles.  
A one-vial formulation of Taxotere
® has recently been 
developed and is likely to be commercially available in 2010 in 
some countries. This formulation consists of a 20-mg/ml 
solution of docetaxel diluted in 50/50 v/v polysorbate 80/ethanol 
and maintains the same docetaxel/polysorbate ratio as in the 
two-vial preparation. Preparation of an infusion solution using 
this 1-vial Taxotere
® is simplified in that no premix solution is 
required and the appropriate dose of concentrate is simply 
added to the infusion bag, with gentle mixing (one-shot 
preparation technique). With no intermediate premix solution 
(which is itself a supersaturated micellar solution and can 
potentially crystallize) [7],
  the risk of crystallization should be 
reduced. 
The aims of this study were to determine the potential storage 
time for Taxotere
® one-vial infusion bags under refrigerated 
conditions with respect to physical stability and to confirm 
chemical stability during the storage period. 
The results of the study were presented as a poster at the 
European Society of Clinical Pharmacy (ESCP) European 
Symposium between October 21 and 23, 2010 [8],
  and are 
discussed in more detail here.
 
 
Materials and methods 
Taxotere
® one-vial infusion solutions were prepared by adding 
200 mg of docetaxel, using a single introduction of 10 ml 
docetaxel concentrate (20 mg/ml) into 250 ml polyethylene bags 
filled with 0.9% saline. Infusion bags were stored under 
refrigeration at 5°C and removed after either two (n=60 bags) or 
seven (n=60 bags) days and assessed immediately and at 
intervals after removal and storage for a further 24 h at ambient 
temperature (about 20°C). Crystallization was assessed by a 
careful visual examination. The chemical stability was assessed 
by determination of the docetaxel content and degradation 
impurities in five of the infusion bags (three bags after 
refrigerated storage for two days and three bags after 
refrigerated storage for seven days) by high-performance liquid 
chromatography.  
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Results 
No visible crystallization was observed in any Taxotere
® one-
vial infusion bags following refrigerated storage for either two or 
seven days and subsequent storage for 24 h at approximately 
20°C. There was no significant evolution of pH, docetaxel 
content or degradation impurities in the infusion bags during this 
time. 
 
Discussion 
Physical and chemical stability of a Taxotere
® infusion depends 
on minimizing the risk of crystallization during storage. Various 
factors potentiate this risk as discussed in the introduction.  
This study sought to control two significant potential risk factors 
for crystallization—intervention into the infusion bag (by using a 
one-step technique) and temperature (by use of refrigerated 
storage). In this way, it appears possible to extend the storage 
time of Taxotere
® one-vial infusion bags from 4 h with the two-
vial infusion preparation to seven days, leading to increased 
convenience and flexibility in the pharmacy and clinic when 
needed. 
Our findings build on those published by Pinguet and 
colleagues, who noted no crystallization at preparation time and 
good physical stability at 24 h for infusion bags prepared using 
the one-vial formulation [9]. Their study also showed that the
preparation time for 1-vial Taxotere
®  was significantly shorter 
than that for 2-vial Taxotere
® and the amount of materials used 
for preparation significantly reduced [9].
 
 
Conclusion 
The new Taxotere
® one-vial formulation is associated with 
reduced risk of precipitation of docetaxel via elimination of the 
premix solution (required for the Taxotere
® two-vial 
presentation) and a one-shot preparation technique (i.e. only 
one intervention into the infusion bag). Moreover, refrigerated 
storage has been shown to extend the physicochemical stability 
of the formulation to up to seven days (versus 4 h with the 
previous formulation). 
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